The drug, Keytruda (pembrolizumab), was tested on more than 600 patients who had melanoma that had spread throughout their bodies. Because so many of the patients in the early testing showed significant long-lasting responses, the study was continued and the FDA granted the drug “breakthrough therapy” status, allowing it to be fast-tracked for approval…
The study evaluated two groups of 31 men with prostate cancer that had spread and whose blood levels of prostate-specific antigen (PSA) were still rising despite low testosterone levels. Investigators gave each man either enzalutamide (Xtandi) or abiraterone (Zytiga) and tracked whether their PSA levels continued to rise, an indication that the drugs were not working. In the enzalutamide group, none of 12 patients whose blood samples tested positive for AR-V7 responded to the drug, compared with 10 responders among 19 men who had no AR-V7 detected. In the abiraterone group, none of six AR-V7-positive patients responded, compared with 17 responders among 25 patients lacking AR-V7. …
Now a team of scientists, led by Prof. Taeghwan Hyeon at the Institute for Basic Science (IBS)/Seoul National University and Prof. …
“These are amazingly useful particles,” noted co-first author Yuanpei Li, a research faculty member in the Lam laboratory. “As a contrast agent, they make tumors easier to see on MRI and other scans…
The new study suggests that treatment with poly (ADP-ribose) polymerase (PARP) inhibitors, together with standard chemotherapy drugs, could be more effective in combating leukemia. In the same study, researchers found that the inactivation of RUNX genes causes DNA repair defects and promotes the development of leukemia and other cancers…
“Scientists have long observed that human and mouse cancers contain a lot of nerves in and around the tumor cells,” said Dr. …
Their paper, published in Proceedings of the National Academy of Sciences, is the culmination of nearly a decade of research into the role of arginine — and its deprivation — in the generation of excessive autophagy, a process in which the cell dies by eating itself. Study co-author Hsing-Jien Kung, a cancer biologist and UC Davis professor emeritus who now leads the National Health Research Institutes in Taipei, Taiwan, first discovered the mechanism by which arginine deprivation works in 2009, when he led basic science research at the UC Davis Comprehensive Cancer Center. “Traditional cancer therapies involve ‘poisoning’ by toxic chemicals or ‘burning’ by radiation cancer cells to death, which often have side effects,” Kung said…
Their paper, published in Proceedings of the National Academy of Sciences, is the culmination of nearly a decade of research into the role of arginine — and its deprivation — in the generation of excessive autophagy, a process in which the cell dies by eating itself. Study co-author Hsing-Jien Kung, a cancer biologist and UC Davis professor emeritus who now leads the National Health Research Institutes in Taipei, Taiwan, first discovered the mechanism by which arginine deprivation works in 2009, when he led basic science research at the UC Davis Comprehensive Cancer Center. “Traditional cancer therapies involve ‘poisoning’ by toxic chemicals or ‘burning’ by radiation cancer cells to death, which often have side effects,” Kung said. “An emerging strategy is to ‘starve’ cancer cells to death, taking advantage of the different metabolic requirements of normal and cancer cells. …
Scientists at The Scripps Research Institute (TSRI) tried a similar strategy when they attempted to disrupt the function of MYC, a cancer regulator thought to be “undruggable.” The researchers found that a credit card-like molecule they developed somehow moves in and disrupts the critical interactions between MYC and its binding partner. The research, published the week of August 11 in the journal Proceedings of the National Academy of Sciences, also shows the drug candidate can stop tumor growth in animal models. …
Cancer Research UK scientists have found a new use for an old drug by showing that it shrinks a particular type of pancreatic cancer tumour and stops it spreading, according to researchpublished in Gut*. The scientists, at the Cancer Research UK Beatson Institute and the University of Glasgow, treated mice with pancreatic cancers caused by known genetic faults with the drug rapamycin**. Previous clinical trials did not find this drug to be effective as a treatment for pancreatic cancers when it was given to all patients with different forms of the disease. But the team’s findings show that a particular type of pancreatic tumour – caused by a fault in the gene PTEN, which is involved in cell growth – may be responsive to the drug after all. …